437 related articles for article (PubMed ID: 11015434)
1. Natural killer T cell activation inhibits hepatitis B virus replication in vivo.
Kakimi K; Guidotti LG; Koezuka Y; Chisari FV
J Exp Med; 2000 Oct; 192(7):921-30. PubMed ID: 11015434
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
[TBL] [Abstract][Full Text] [Related]
3. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection.
Baron JL; Gardiner L; Nishimura S; Shinkai K; Locksley R; Ganem D
Immunity; 2002 Apr; 16(4):583-94. PubMed ID: 11970881
[TBL] [Abstract][Full Text] [Related]
4. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
5. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance.
Ito H; Ando K; Ishikawa T; Nakayama T; Taniguchi M; Saito K; Imawari M; Moriwaki H; Yokochi T; Kakumu S; Seishima M
Int Immunol; 2008 Jul; 20(7):869-79. PubMed ID: 18487227
[TBL] [Abstract][Full Text] [Related]
6. During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment.
Duthie MS; Kahn SJ
Immunology; 2006 Nov; 119(3):355-61. PubMed ID: 16879622
[TBL] [Abstract][Full Text] [Related]
7. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H
J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104
[TBL] [Abstract][Full Text] [Related]
8. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
9. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
[TBL] [Abstract][Full Text] [Related]
10. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
11. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.
Wu J; Huang S; Zhao X; Chen M; Lin Y; Xia Y; Sun C; Yang X; Wang J; Guo Y; Song J; Zhang E; Wang B; Zheng X; Schlaak JF; Lu M; Yang D
J Virol; 2014 Sep; 88(18):10421-31. PubMed ID: 24920792
[TBL] [Abstract][Full Text] [Related]
12. Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.
Inui T; Nakagawa R; Ohkura S; Habu Y; Koike Y; Motoki K; Kuranaga N; Fukasawa M; Shinomiya N; Seki S
J Immunol; 2002 Dec; 169(11):6127-32. PubMed ID: 12444115
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice.
Cavanaugh VJ; Guidotti LG; Chisari FV
J Virol; 1997 Apr; 71(4):3236-43. PubMed ID: 9060687
[TBL] [Abstract][Full Text] [Related]
14. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice.
Kimura K; Kakimi K; Wieland S; Guidotti LG; Chisari FV
J Virol; 2002 Nov; 76(21):10702-7. PubMed ID: 12368312
[TBL] [Abstract][Full Text] [Related]
17. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
18. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B.
Gu Y; Lian Y; Zheng Q; Huang Z; Gu L; Bi Y; Li J; Huang Y; Wu Y; Chen L; Huang Y
BMC Infect Dis; 2020 Jul; 20(1):509. PubMed ID: 32664850
[TBL] [Abstract][Full Text] [Related]
19. Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression.
Kawashima K; Isogawa M; Hamada-Tsutsumi S; Baudi I; Saito S; Nakajima A; Tanaka Y
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209178
[TBL] [Abstract][Full Text] [Related]
20. CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo.
Ilyinskii PO; Wang R; Balk SP; Exley MA
J Virol; 2006 Jul; 80(14):7146-58. PubMed ID: 16809320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
